



Daniel G. Wildman



Dan Wildman is Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc., a Johnson & Johnson Company. Dan leads a global business dedicated to delivering innovative and life-saving solutions to surgeons with a commitment to advancing the future of biosurgery beyond hemostasis, to seal leaks, join structures and enhance healing. In this role, Dan has responsibility for the Ethicon Biosurgery portfolio which offers the world's most complete line of absorbable hemostats that address a range of bleeding and leaking situations – from routine to problematic – during surgical procedures. He also has responsibility for Guangzhou Bioseal Biotech Co., Ltd. based in China, a stand-alone company that manufactures products within the Ethicon Biosurgery portfolio. He is a member of the Global Surgery Group, Group Operating Committee.

Dan has held roles of increasing complexity and responsibility within the medical device industry over the past 25 years. He began his career with Johnson & Johnson in 1981 with the wound management business as a sales representative in the Patient Care Division. He then moved on to roles in sales, marketing, and product development with both domestic and global responsibilities for companies such as Collagen Corporation, SCIMED Life Systems and Boston Scientific.

In 2001, Dan returned to his roots at Johnson & Johnson as Vice President, Sales, Marketing and Product Development for Codman, a DePuy operating company, where he produced record results on a consistent basis. He joined Ethicon in his current role in 2002, where he has led his team in achieving double-digit revenue and earnings growth.

Dan is an accomplished global leader, throughout his career he has earned a solid reputation for his strategic vision, ability to execute and his commitment to people development and Our Credo.

Dan received a Bachelor of Arts degree in Economics from St. Lawrence University in New York.

01/2014